{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T11:41:41Z","timestamp":1782042101970,"version":"3.54.5"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Tumour necrosis factor \u03b1 (TNF-\u03b1) inhibitor (TNFi)-induced psoriasiform eruptions are a well-known phenomenon among adults. However, data are limited regarding this reaction in children.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To describe in paediatric patients with inflammatory bowel disease (IBD) the clinical characteristics of TNFi-induced psoriasiform eruptions and the outcomes of various therapeutic options.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We reviewed the medical charts of paediatric patients (aged &amp;lt; 18\u2005years) with IBD who developed TNFi-induced psoriasiform eruptions during 2006\u20132022.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 454 patients with IBD treated with TNFis, 58 (12.8%) were diagnosed with TNFi-induced psoriasiform eruptions, of whom 51 were included in the study. The female to male ratio was 1 : 1.3. The median age at skin eruption was 14.11 [interquartile range (IQR) 12.11\u201316.05] years. The median elapsed time to eruption appearance was 15.00\u2005months (IQR 7.00\u201324.00) after initiation of the treatment. All 51 patients were treated with topical steroids and 17 (33%) needed systemic treatment (phototherapy, methotrexate or acitretin). Sixteen of 51 patients (31%) needed to stop TNFi treatment because of an intractable eruption. Female patients, patients with inflammatory alopecia and patients who were treated with methotrexate or phototherapy were more prone to stop TNFis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>TNFi-induced psoriasiform eruptions are common in paediatric patients with IBD. The eruption may appear months or even years after treatment initiation. Almost one-third of the described patients had to replace their treatment because of a recalcitrant cutaneous eruption. This indicates that a multidisciplinary approach is required.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ced\/llae432","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T11:48:37Z","timestamp":1728906517000},"page":"558-563","source":"Crossref","is-referenced-by-count":3,"title":["Paradoxical psoriasiform skin eruption in paediatric patients with inflammatory bowel disease treated with tumour necrosis factor-\u03b1 inhibitors"],"prefix":"10.1093","volume":"50","author":[{"given":"Daniel","family":"Hilewitz","sequence":"first","affiliation":[{"name":"School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv University , Tel Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Yacobovitz","sequence":"additional","affiliation":[{"name":"School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv University , Tel Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiran","family":"Reiss-Huss","sequence":"additional","affiliation":[{"name":"School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv University , Tel Aviv ,","place":["Israel"]},{"name":"Pediatric Dermatology Unit, Schneider Children's Medical Center of Israel , Petah Tikva ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manar","family":"Matar","sequence":"additional","affiliation":[{"name":"School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv University , Tel Aviv ,","place":["Israel"]},{"name":"Institute of Gastroenterology, Nutrition and Liver Diseases, Schneider Children\u2019s Medical Centre , Petach-Tikva ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Weintraub","sequence":"additional","affiliation":[{"name":"School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv University , Tel Aviv ,","place":["Israel"]},{"name":"Institute of Gastroenterology, Nutrition and Liver Diseases, Schneider Children\u2019s Medical Centre , Petach-Tikva ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5980-2954","authenticated-orcid":false,"given":"Dror S","family":"Shouval","sequence":"additional","affiliation":[{"name":"School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv University , Tel Aviv ,","place":["Israel"]},{"name":"Institute of Gastroenterology, Nutrition and Liver Diseases, Schneider Children\u2019s Medical Centre , Petach-Tikva ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lev","family":"Pavlovsky","sequence":"additional","affiliation":[{"name":"School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv University , Tel Aviv ,","place":["Israel"]},{"name":"Division of Dermatology, Rabin Medical Center , Petah Tikva ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rivka","family":"Friedland","sequence":"additional","affiliation":[{"name":"School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv University , Tel Aviv ,","place":["Israel"]},{"name":"Pediatric Dermatology Unit, Schneider Children's Medical Center of Israel , Petah Tikva ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,14]]},"reference":[{"key":"2025022416233971300_llae432-B1","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3389\/fphar.2017.00460","article-title":"Drugs for autoimmune inflammatory diseases: from small molecule compounds to anti-TNF biologics","volume":"8","author":"Li","year":"2017","journal-title":"Front Pharmacol"},{"key":"2025022416233971300_llae432-B2","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/apt.15097","article-title":"Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease","volume":"49","author":"Shivaji","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2025022416233971300_llae432-B3","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(17)31189-3","article-title":"Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial","volume":"390","author":"Papp","year":"2017","journal-title":"Lancet"},{"key":"2025022416233971300_llae432-B4","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3389\/fphar.2019.00282","article-title":"Paradoxical skin reactions to biologics in patients with rheumatologic disorders","volume":"10","author":"Garcovich","year":"2019","journal-title":"Front Pharmacol"},{"key":"2025022416233971300_llae432-B5","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/art.23835","article-title":"Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action","volume":"59","author":"Collamer","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2025022416233971300_llae432-B6","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.jaad.2020.12.010","article-title":"Paradoxical eruptions to targeted therapies in dermatology: a systematic review and analysis","volume":"86","author":"Murphy","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2025022416233971300_llae432-B7","doi-asserted-by":"crossref","DOI":"10.1177\/17562848211053112","article-title":"Clinical approach to skin eruptions induced by anti-TNF agents among patients with inflammatory bowel diseases: insights from a multidisciplinary IBD-DERMA clinic","volume":"14","author":"Yanai","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"key":"2025022416233971300_llae432-B8","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.crohns.2011.10.007","article-title":"Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases","volume":"6","author":"Guerra","year":"2012","journal-title":"J Crohns Colitis"},{"key":"2025022416233971300_llae432-B9","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/apt.13352","article-title":"Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study","volume":"42","author":"Pugliese","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"2025022416233971300_llae432-B10","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.crohns.2012.08.007","article-title":"Induction or exacerbation of psoriatic lesions during anti-TNF-\u03b1 therapy for inflammatory bowel disease: a systematic literature review based on 222 cases","volume":"7","author":"Denadai","year":"2013","journal-title":"J Crohns Colitis"},{"key":"2025022416233971300_llae432-B11","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jamadermatol.2023.0549","article-title":"Paradoxical psoriasiform eruptions in children receiving tumor necrosis factor \u03b1 inhibitors","volume":"159","author":"Eickstaedt","year":"2023","journal-title":"JAMA Dermatol"},{"key":"2025022416233971300_llae432-B12","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1177\/1203475420917387","article-title":"Skin manifestations in pediatric patients treated with a TNF-alpha inhibitor for inflammatory bowel disease: a retrospective study","volume":"24","author":"Cossio","year":"2020","journal-title":"J Cutan Med Surg"},{"key":"2025022416233971300_llae432-B13","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/MPG.0b013e31828390ba","article-title":"Infliximab-induced psoriasis and psoriasiform skin lesions in pediatric Crohn disease and a potential association with IL-23 receptor polymorphisms","volume":"56","author":"Sherlock","year":"2013","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"2025022416233971300_llae432-B14","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1111\/pde.14712","article-title":"Paradoxical psoriasis in pediatric patients: a systematic review","volume":"38","author":"Cyrenne","year":"2021","journal-title":"Pediatr Dermatol"},{"key":"2025022416233971300_llae432-B15","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1093\/ibd\/izy112","article-title":"Dermatological manifestations in pediatric patients with inflammatory bowel diseases on anti-TNF therapy","volume":"24","author":"Sridhar","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2025022416233971300_llae432-B16","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1097\/MIB.0000000000000088","article-title":"Skin reactions during anti-TNF\u03b1 therapy for pediatric inflammatory bowel disease: a 2-year prospective study","volume":"20","author":"M\u00e4lk\u00f6nen","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"2025022416233971300_llae432-B17","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1111\/ijd.14072","article-title":"Clinical management of anti-TNF-alpha-induced psoriasis or psoriasiform lesions in inflammatory bowel disease patients: a systematic review","volume":"57","author":"Melo","year":"2018","journal-title":"Int J Dermatol"},{"key":"2025022416233971300_llae432-B18","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1093\/ecco-jcc\/jjac035","article-title":"How to manage inflammatory bowel disease patients when they withdraw anti-tumour necrosis factor [anti-TNF] due to severe anti-TNF-induced skin lesions? A multicentre cohort study","volume":"16","author":"Cottron","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2025022416233971300_llae432-B19","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s40272-021-00440-8","article-title":"Paradoxical psoriasis in children receiving anti-TNF\u03b1 treatment for inflammatory\/autoimmune disease","volume":"23","author":"Rosenwasser","year":"2021","journal-title":"Paediatr Drugs"},{"key":"2025022416233971300_llae432-B20","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1136\/gutjnl-2012-302853","article-title":"Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-\u03b3-expressing Th1 cells and IL-17A\/IL-22-expressing Th17 cells and respond to anti-IL-12\/IL-23 antibody treatment","volume":"63","author":"Tillack","year":"2014","journal-title":"Gut"},{"key":"2025022416233971300_llae432-B21","first-page":"69","article-title":"Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn\u2019s disease","volume":"12","author":"Matsumoto","year":"2018","journal-title":"Biologics"},{"key":"2025022416233971300_llae432-B22","doi-asserted-by":"crossref","first-page":"e14883","DOI":"10.1111\/dth.14883","article-title":"Ustekinumab for the treatment of paradoxical skin reactions and cutaneous manifestations of inflammatory bowel diseases","volume":"34","author":"Wu","year":"2021","journal-title":"Dermatol Ther"},{"key":"2025022416233971300_llae432-B23","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/ecco-jcc\/jjac055","article-title":"Outcomes of children with inflammatory bowel disease who develop anti-tumor necrosis factor-induced skin reactions","volume":"16","author":"Dolinger","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2025022416233971300_llae432-B24","doi-asserted-by":"crossref","first-page":"G155","DOI":"10.1152\/ajpgi.00311.2015","article-title":"JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines","volume":"310","author":"Danese","year":"2016","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2025022416233971300_llae432-B25","doi-asserted-by":"crossref","first-page":"100211","DOI":"10.1016\/j.jtauto.2023.100211","article-title":"Paradoxical psoriasis: the flip side of idiopathic psoriasis or an autocephalous reversible drug reaction?","volume":"7","author":"Lu","year":"2023","journal-title":"J Transl Autoimmun"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llae432\/60884893\/llae432.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/3\/558\/60884893\/llae432.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/3\/558\/60884893\/llae432.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T16:23:58Z","timestamp":1740414238000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/3\/558\/7821063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,14]]},"references-count":25,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,10,14]]},"published-print":{"date-parts":[[2025,2,24]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llae432","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,10,14]]}}}